## VRTX: Vertex Pharmaceuticals Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($439.51)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12**
- Source: Business Wire | 20251222T210217 | Neutral | Relevance: 100%
- Vertex Pharmaceuticals Incorporated announced that its CEO and President, Dr. Reshma Kewalramani, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 5:15 p.m. ET. A live webcast of the presentation will be available on the Vertex website, with a replay archived afterward. The company is a global biotechnology firm focusing on transformative medicines for serious diseases.

**2. Flputnam Investment Management Co. Sells 3,065 Shares of Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251221T114028 | Somewhat-Bullish | Relevance: 100%
- Flputnam Investment Management Co. has reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 8.1%, selling 3,065 shares. Despite this, institutional ownership remains high at 90.96%, with other major funds increasing their positions. The company reported an EPS beat and revenue growth, and analysts maintain a "Moderate Buy" rating with an average target price of $498.42.

**3. Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch**
- Source: ts2.tech | 20251220T230851 | Somewhat-Bullish | Relevance: 100%
- Vertex Pharmaceuticals (VRTX) is facing scrutiny as investors assess its efforts to diversify beyond its dominant cystic fibrosis (CF) business with new launches and late-stage programs. Key developments include positive pediatric data for Casgevy, the commercial ramp-up of Journavx, and significant momentum in its kidney disease pipeline. Analysts maintain a constructive outlook, focusing on CF's cash flow, the potential of new therapies, and the scaling challenges for newer products amid an evolving drug pricing environment.

**4. Congress Asset Management Co. Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251221T093654 | Neutral | Relevance: 100%
- Congress Asset Management Co. reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 14.4% in the third quarter, selling 27,129 shares and leaving it with 160,875 shares valued at approximately $63.0 million. Despite this, analysts largely maintain a "Moderate Buy" rating with an average price target of $498.42, and several firms have recently raised their price targets or upgraded the stock. However, significant insider selling has occurred, with insiders offloading 151,073 shares worth about $67.33 million in the last quarter.

**5. Redhawk Wealth Advisors Inc. Lowers Stake in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251220T120823 | Somewhat-Bullish | Relevance: 100%
- Redhawk Wealth Advisors Inc. significantly reduced its holdings in Vertex Pharmaceuticals by 78.9% in the third quarter, decreasing its stake to 1,110 shares. This move comes as insiders sold over $67 million worth of shares, despite Vertex Pharmaceuticals exceeding Q3 earnings and revenue expectations with an 11% revenue increase. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $498.42.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $515 | $460 | +12% |
| 2025-12-05 | Morgan Stanley | $564 | $516 | +9% |
| 2025-12-03 | Morgan Stanley | $516 | $438 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-05 | Morgan Stanley | main | Overweight |
| 2025-12-03 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($3.52M) |
| Sells | 10 ($11.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Capital World Invest: 10.2% (-9.8%)
- Vanguard Group Inc: 9.5% (+1.0%)
- Blackrock Inc.: 8.8% (+1.7%)
- Capital Research Glo: 6.5% (+2.8%)
- JPMORGAN CHASE & CO: 5.1% (+119.3%)

### Key Risks

1. Heavy insider selling: $11M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.58 indicates undervaluation relative to growth. Forward P/E 22.7x stretched relative to 10% growth. Quality metrics strong (ROE 22%, ROA 12%, margin 31%). Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.44), $1.1B free cash flow. Analyst sentiment positive (3 raises, avg +13%). Insider selling cluster ($11.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $118.0B |
| Beta | 0.32 |
| 52W Range | $362.50 - $519.68 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.58 |
| Forward P/E | 22.7 |
| Current P/E | 25.0 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.46% (CS: 75) | Neutral |
| RSI_14 | 62.5 | Neutral |
| MACD Histogram | 0.38 | Bullish |
| vs SMA20 | 1.034x | Above |
| vs SMA50 | 1.067x | Above |
| vs SMA200 | 1.044x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $460.31
- **Stop Loss:** $439.51 (4.5% risk)
- **Target:** $481.11 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 57
- **Position Value:** $26,237.67
- **Portfolio %:** 26.24%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-09 (Est: $5.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.58 | $4.80 | +4.9% |
| 2025Q2 | $4.25 | $4.52 | +6.3% |
| 2025Q1 | $4.29 | $4.06 | -5.4% |
| 2024Q4 | $4.02 | $3.98 | -1.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*